Session » Epidemiology and Public Health Poster II

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1204

An Increased Risk of Heart Failure and Heart Failure-Related Death Persists in Rheumatoid Arthritis: A National, Matched Cohort Study from 2000 to 2019

1:00PM-3:00PM: Abstract Number: 1206

Association Between Different Alcoholic Beverages and Serum Urate Level: A Cross-Sectional Study Using Large Medical Checkup Data

1:00PM-3:00PM: Abstract Number: 1201

Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection

1:00PM-3:00PM: Abstract Number: 1192

Celiac Disease in Patients with Systemic Lupus Erythematosus: An Analysis of Nationwide Inpatient Sample

1:00PM-3:00PM: Abstract Number: 1202

Clinical Profile and Trend of Vasculitis in Patients with Acute Coronary Syndrome – Insight from National Database 2010 to 2019

1:00PM-3:00PM: Abstract Number: 1205

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases

1:00PM-3:00PM: Abstract Number: 1208

Development and Validation of a Prognostic Model for Methotrexate Discontinuation with Abnormal Monitoring Blood-test Results: A Cohort Study Using Data from Clinical Practice Research Datalink Gold and Aurum

1:00PM-3:00PM: Abstract Number: 1188

Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting

1:00PM-3:00PM: Abstract Number: 1195

Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain

1:00PM-3:00PM: Abstract Number: 1197

Folic Acid and Methotrexate Use and Their Association with COVID-19 Diagnosis and Mortality: An Analysis from the UK Biobank

1:00PM-3:00PM: Abstract Number: 1212

Immunogenicity After Primary COVID-19 Vaccination in Patients with Immune-mediated Inflammatory Diseases: A Comparative Cohort Study

1:00PM-3:00PM: Abstract Number: 1211

Impact of Change in Biologic Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of RA Patients

1:00PM-3:00PM: Abstract Number: 1209

Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients

1:00PM-3:00PM: Abstract Number: 1214

In-hospital Outcomes of Autoimmune Diseases Complicated by Interstitial Lung Disease: A National Inpatient Sample Analysis

1:00PM-3:00PM: Abstract Number: 1196

Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study

1:00PM-3:00PM: Abstract Number: 1194

Key Self-reported Determinants of COVID-19 Vaccine Acceptance Among Persons with and Without Autoimmune Disease

1:00PM-3:00PM: Abstract Number: 1190

Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an Incident Population-based Cohort (1980-2018)

1:00PM-3:00PM: Abstract Number: 1189

Natural Language Processing of Chest CT Reports as a Novel Method of Identifying RA-ILD in Real-World Data

1:00PM-3:00PM: Abstract Number: 1187

Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting

1:00PM-3:00PM: Abstract Number: 1207

Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid

1:00PM-3:00PM: Abstract Number: 1193

Seasonal Variation of Hospitalizations and In-Hospital Mortality Related to Systemic Lupus Erythematosus Among Adults in the United States: An Analysis of Nationwide Inpatient Sample

1:00PM-3:00PM: Abstract Number: 1203

The Association Between Anti-Citrullinated Peptide Antibodies and Subclinical Interstitial Lung Disease in Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis

1:00PM-3:00PM: Abstract Number: 1191

The Risk of Major Adverse Cardiovascular Events in Patients with Systemic Sclerosis: A Population-Based, Matched Cohort Study

1:00PM-3:00PM: Abstract Number: 1186

The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States

1:00PM-3:00PM: Abstract Number: 1213

Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021

1:00PM-3:00PM: Abstract Number: 1210

Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 1199

Validation of New Medication User Definitions in Single-Specialty EHR Data

1:00PM-3:00PM: Abstract Number: 1198

Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 1200

Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial: Outcomes over 7 Years

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].